Shattuck Labs, Inc. (STTK)
Nasdaq · Healthcare · Biotechnology
$6.50−3.42%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $652M
- 52-week range
- $1.70 – $8.33
- 52-week change
- +159.85%
- EPS (trailing)
- −$0.47
- Analyst rating
- 1.3 Strong buy
- Next earnings
- Nov 12, 2026
Fiscal year to Dec 2025
- Revenue
- $1.0M (−82.52%)
- Net income
- −$48.8M
- Operating margin
- −5150.8%
- Diluted EPS
- −$0.70
- Free cash flow
- −$40.0M
From the company’s annual report on SEC EDGAR.
About Shattuck Labs, Inc.
Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study. It is also involved in the development of various preclinical DR3-based bispecific antibodies for the treatment of patients with inflammatory bowel disease or other immune-mediated indications; and TRIM7, an oncology-focused program. The company was incorporated in 2016 and is headquartered in Austin, Texas.
Headquarters: Austin, United States · 40 employees · shattucklabs.com